Officials with United Therapeutics celebrated an Oct. 20 opening of their new xeno-organ manufacturing site in Houston’s Generation Park, according to an Oct. 20 news release.
The details
United Therapeutics now joins Generation Park’s growing biotechnology hub that has recently welcomed Eli Lilly and Bristol Myers Squibb, according to previous reporting.
The new facility is designed to enable United Therapeutics to scale commercial production of its xeno-organs, or organs that can be transplanted from one species to another, following approval of the products, according to the news release.
United Therapeutics chairperson and CEO Martine Rothblatt touted the new facility.
“Every day, people with end-stage organ disease die waiting for an organ that never comes,” Rothblatt said in the news release. “With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them.”
United Therapeutics is conducting clinical trials for three investigational xenotransplantation products that could be used to treat patients with heart and kidney failure, according to the news release.
Some context
Generation Park, a 4,300-acre master-planned community in Houston, is also home to other life sciences offerings, including the San Jacinto College Center for Biotechnology and BioHub Two, a 45-acre biomanufacturing campus.
In August, biopharmaceutical company Bristol Myers Squibb selected Generation Park for its new $2.3 billion manufacturing campus, according to previous reporting.
In September 2025, Eli Lilly and Company announced plans to build a $6.5 billion manufacturing facility in the master-planned community.
